Content
02/13/2024
Chapel Hill, NC USA
Areteia Therapeutics
completed $75 million Series A Round funding. Investors include
Viking Global Investors, Saturn Partners, Maverick Capital, Google Ventures, Bain Capital Ventures, ARCH Venture Partners.
About
Areteia Therapeutics is a new biotechnology company committed to putting asthma patients in better control of their disease—and back in control of their lives—with the first potential oral drug for eosinophilic asthma.
Startup
Sector:
Biotech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
